Can phenytoin (antiepileptic medication) cause immediate hallucinations after a dose, especially in patients with a history of neurological or psychiatric conditions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 17, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Phenytoin Cause Immediate Hallucinations After a Dose?

Yes, phenytoin can cause hallucinations shortly after administration, though this is an uncommon adverse effect that can occur even at therapeutic or subtherapeutic serum levels.

Documented Cases of Phenytoin-Induced Hallucinations

The evidence clearly demonstrates that phenytoin can trigger acute visual hallucinations:

  • A 4-year-old child developed complex visual hallucinations and psychomotor agitation early after intravenous phenytoin administration, with symptoms occurring while serum phenytoin concentrations were below therapeutic range 1
  • The temporal relationship between phenytoin initiation and symptom onset, followed by resolution upon drug withdrawal, strongly suggested causation 1
  • Another pediatric case (9-year-old) experienced intermittent complex visual hallucinations after starting antiepileptic therapy including phenytoin, attributed to drug side effects after excluding other etiologies 2

Mechanism and Clinical Context

While the FDA label does not specifically list hallucinations as a common adverse effect, it does note that serum levels sustained above the optimal range may produce confusional states referred to as "delirium," "psychosis," or "encephalopathy" 3. However, the pediatric case reports demonstrate hallucinations can occur even at subtherapeutic levels 1.

Phenytoin encephalopathy manifesting as cognitive impairment represents an important adverse neurological effect 4, and psychiatric manifestations of toxicity including psychosis and hallucinations are less widely recognized than classic neurologic signs 2.

High-Risk Populations

Certain patient groups face elevated risk:

  • Patients with hypoalbuminemia are at particular risk for severe neurological side effects including disorientation, myoclonia, hallucinations, and drowsiness, even when total phenytoin concentrations appear therapeutic 5
  • In hypoalbuminemic states, free (unbound) phenytoin levels become toxic while total levels remain in the therapeutic range of 8-20 mg/L 5
  • Patients with intellectual disability are especially susceptible to balance disturbances and cognitive dysfunction from phenytoin 4

Critical Monitoring Points

When phenytoin-induced hallucinations are suspected:

  • Check both total and free phenytoin levels, particularly in patients with low serum albumin (below 25 g/L) 5
  • Therapeutic free phenytoin range is 0.5-2 mg/L; toxic levels of 4-8 mg/L have been associated with hallucinations 5
  • At the first sign of acute toxicity including hallucinations, plasma level measurement is recommended, with dose reduction if levels are excessive or drug discontinuation if symptoms persist 3
  • Rule out non-convulsive status epilepticus, CNS infection, metabolic disorders, and underlying psychiatric disease 1

Clinical Pitfalls to Avoid

  • Do not assume therapeutic total phenytoin levels exclude toxicity in patients with hypoalbuminemia—always consider free phenytoin levels 5
  • Visual hallucinations can mimic delirium tremens or other psychiatric emergencies, potentially leading to misdiagnosis 1
  • Hallucinations may occur rapidly after dose administration, not just with chronic toxicity 1
  • The absence of classic toxicity signs (ataxia, nystagmus, dysarthria) does not exclude phenytoin-induced psychiatric symptoms 2

References

Research

Phenytoin-induced visual disturbances mimicking Delirium Tremens in a child.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2010

Research

Phenytoin: effective but insidious therapy for epilepsy in people with intellectual disability.

Journal of intellectual disability research : JIDR, 1998

Research

[Severe phenytoin intoxication in patients with hypoalbuminaemia].

Nederlands tijdschrift voor geneeskunde, 2007

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.